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BACKGROUND Platinum-chromium alloy has been recently incorpo-
rated to the drug-eluting stent platforms, mainly everolimus-eluting
stents (Promus Element -PE- stent). The objective of the study was to
evaluate the efﬁcacy and safety of PE in comparison with other sec-
ond-generation drug-eluting stents.
METHODS A meta-analysis from 5 published randomized trials that
compared PE with other second-generation drug-eluting stents was
performed. Overall, 7,896 patients were included: 3,330 allocated to
PE, and 4,566 to other stents (3,415 to cobalt-chromium everolimus-
eluting, 906 to zotarolimus-eluting, and 245 to biolimus-eluting
stent). In all trials, planned follow-up was 12 months.
RESULTS Clinical events at 12 months were infrequent (target lesion
revascularization < 2%), and numerically lower in patients allocated
to PE, but differences were not statistically different (see table). The
rate of deﬁnitive/probable stent thrombosis after PE implantation at 1
year was < 0.5%.PE stent Control p value OR (95% CI)Target vessel failure (%) 4.6 5.3 0.65 0.95 (0.77, 1.18)Death (%) 2.5 2.7 0.96 0.99 (0.74, 1.33)Cardiac death (%) 1.2 1.3 0.59 0.89 (0.59 1.35)Infarction (%) 2.1 2.7 0.51 0.90 (0.67, 1.22)Target vessel
revascularization (%)2.2 2.6 0.70 0.74 (0.70, 1.27)Target lesion
revascularization (%)1.6 1.8 0.88 0.97 (0.69, 1.38)Stent thrombosis (%) 0.46 0.63 0.37 0.76 (0.42, 1.39)CONCLUSIONS Clinical outcomes of patients treated with the plat-
inum-chromium everolimus-eluting stent Promus Element is excel-
lent, with rates of target lesion revascularization and stent thrombosis
at 1 year of 1.8% and 0.46%, respectively.
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BACKGROUND The relative safety of drug-eluting stents (DES) and bare-
metal stents (BMS) in primary percutaneous coronary intervention (PPCI)
continues to be debated. We compared the long-term clinical outcomes
between 2nd generation DES and BMS for primary percutaneous coronary
intervention (PCI) using network meta-analysis.
METHODS Randomized controlled trials comparing stent types (1st
generation DES, 2nd generation DES or BMS) were considered for
inclusion. A search strategy used Medline, Embase, Cochrane da-
tabases and proceedings of the international meetings. Information
about study design, inclusion criteria and sample characteristics
were extracted. Network meta-analysis was used to pool direct
(comparison of 2nd generation DES to BMS) and indirect evidence
(1st generation DES with BMS and 2nd generation DES) from the
randomized trials.
RESULTS 12 trials comparing all stents types including 9673 pa-
tients randomly assigned to treatment groups were analyzed. Sec-
ond generation DES was associated with signiﬁcantly lower
incidence of deﬁnite or probable ST (OR 0.59, CI 0.39-0.89), MI (OR
0.59, 95% CI 0.39-0.89) and TVR at 3 years (OR 0.50: CI 0.31-0.81)
compared to BMS. In addition, there was a signiﬁcantly lower
incidence of MACE with 2nd generation DES vs. BMS (OR 0.54, CI
0.34-0.74) at 3 years. These were driven by a higher rate of TVR, MI
and stent thrombosis in the BMS group at 3 years. There was a non-
signiﬁcant reduction in the overall and cardiac mortality [OR 0.83,
CI (0.60-1.14), OR 0.88, CI (0.6-1.28)] with the use of 2nd generation
DES vs. BMS at 3 years.
CONCLUSIONS Network meta-analysis of randomized trials of pri-
mary PCI demonstrated lower incidence of MACE, MI, TVR and stent
thrombosis with 2nd generation DES compared to BMS. Use of second
generation DES for PCI in STEMI was not associated with adverse
events compared to BMS.
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BACKGROUND Polymer-free controlled drug elution has proved
challenging for surface-modiﬁed drug eluting stents. Drug-ﬁlled
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for polymer-free drug delivery in which the drug is contained in a
hollow stent and released through laser drilled holes along the ablu-
minal surface of the stent. We hypothesized that hole-size can
modulate in vivo drug release kinetics from DFS.
METHODS Sterilized DFS (96 mg sirolimus/3.018 mm) with hole di-
ameters of 15, 20 or 25 mm were mounted on a Microtrac Stent De-
livery System and implanted in non-diseased porcine coronary arteries
(target stent-to-artery ratio between 1.10:1 and 1.15:1) for 1 to 90 days
(n¼6/time point). Explanted stents and arteries were analyzed for
sirolimus content using liquid chromatography coupled with ultra
violet detection, and liquid chromatography coupled with tandem
mass spectrometry detection, respectively. Drug release was ﬁt to a bi-
exponential model with zero plateau and tissue content to a mono-
exponential model with the same late half-life as late drug release but
a positive plateau. Bioequivalence analysis was performed following
FDA guidance documentation from 2001 to determine if drug delivery
from DFS with different hole-sizes was statistically different. This
analysis evaluates the ratio of the geometric least square means of test
arms across multiple time points. Test arms are considered bio-
equivalent if their geometric ratio is within the bounds of 0.8 – 1.25.
RESULTS Sirolimus release kinetics from DFS were biexponential (Fig
A, R2>0.99), speaking to the existence of an easily available and
releasable pool of drug that elutes within the ﬁrst day (ﬁrst time point)
following arterial implantation, plus a pool of sustained-eluting drug
with a half-life of 28-32 days. Notably, the fraction of drug load that is
sustained-eluting and its half-life of release both decreased with
increasing hole-size (Fig B). Tissue content tracked the ﬁrst order
elution of the sustained-eluting drug pool down to an apparent
plateau level of 0.510.03 ng/mg (Fig C) and was not statistically
different for any of the hole sizes evaluated (15, 20, and 25 mm).
CONCLUSIONS Though drug in tissue from DFS with hole-sizes of 15
to 25mm were bioequivalent, hole-size emerged as a design parameter
for predictably titrating local tissue retention of DFS eluted drug.
CATEGORIES CORONARY: Stents: Drug-Eluting
KEYWORDS Drug-eluting stent, In Vivo, Pharmacokinetics
TCT-555
Impact of Stent Size Selection on Acute and Long-Term Outcomes after
Drug-Eluting Stent Implantation in De Novo Coronary Lesions
Hideki Kitahara,1 Kozo Okada,1 Yuhei Kobayashi,1 Takumi Kimura,1
Paul Yock,1 Peter J. Fitzgerald,1 Yasuhiro Honda1
1Stanford University, Stanford, CA
BACKGROUND The advent of bioresorbable scaffolds is redrawing
attention to accurate device size selection. While signiﬁcant undersizing
often results in incomplete strut apposition (ISA) or underexpansion,
possible impact of oversized stent implantation on arterial wall injury has
not been systematically investigated with drug-eluting stents (DES).
METHODS To evaluate the effect of stent oversizing on acute and
long-term outcomes, serial (baseline and 6-12 months) coronary
angiography and IVUS were performed in 2931 lesions treated with
DES (355 sirolimus, 846 paclitaxel, 1387 zotarolimus, and 343everolimus). The degree of stent oversizing (%SO) to angiographic
reference vessel diameter (RVD) was calculated as (nominal stent
diameter – RVD) / RVD x 100 (%). Post-procedural stent expansion was
calculated by IVUS as minimum stent area divided by the average
reference lumen area. Clinical outcomes including target lesion
revascularization (TLR) and stent thrombosis were followed for 1 year.
RESULTS Overall, smaller pre-procedural RVD was linearly associated
withhigher%SO (r¼-0.670, p<0.001). Signiﬁcant stent oversizing (deﬁned
as%SO>10%)was found in82%of small RVD (<2.75mm)group and33%of
larger RVD (2.75mm) group. The signiﬁcant oversizing group underwent
less post-dilatation (p¼0.002), but achieved greater stent expansion
(p<0.001) and less ISA (p<0.001) without increase of edge dissection after
procedure. When stratiﬁed by vessel size and stent oversizing (no differ-
ence in DES type among the 4 groups, p¼0.525), progressive decreases of
angiographic binary restenosis and TLR rates (left ﬁgure) were found in
favor of larger vessel size and oversized stents. Stent thrombosis was
observed the most in the small RVD with low %SO group compared with
the other subgroups (p¼0.040) (right ﬁgure).
CONCLUSIONS In this pooled data analysis, no negative impact of stent
oversizing was documented with respect to procedural and long-term
clinical outcomes. Clinical adverse events appeared to be primarily
related to vessel size itself, rather than the selection of a stent larger than
the vessel size. In particular, small vessels treated with a smaller stent
were associated with greater adverse events, suggesting that aggressive
selection of larger stents with appropriate attention to edge effects may
optimize long-term outcomes even in DES implantation.
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